Singapore enhances neutralizing antibody testing service
Singapore enhances neutralizing antibody testing service
12 April 2021 | News
Image credit- prnewswire
GenScript Biotech Corporation, Parkway Laboratories and the Diagnostics Development (DxD) Hub announced their collaboration to provide the cPass™ SARS-CoV-2 neutralizing antibody test in Singapore through Parkway's panel of specialist and GP clinics.
Neutralizing antibodies are a small percentage of antibodies that bind to sites on the virus and inhibit entry of that virus into the host. Unlike the many COVID-19 lab-based antibody test kits commercially available, cPass™ can detect functional neutralizing antibodies.
Traditionally, measuring neutralizing antibodies requires the use of live virus, cells, highly skilled operators, and complex laboratory procedures that require several days in the laboratory to obtain results and limit their widespread use.